Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
VVT Medical
Kfar Saba, Israel
- Ownership
- Private
- Development stage
- Other
01
Overview
VVT Medical's ScleroSafe platform is FDA cleared and CE marked for endovenous chemical ablation of superficial varicose veins, using a unique dual-syringe, non-thermal, non-tumescent minimally invasive approach with reported quick recovery and reduced side effects[1][3]. V-Block further addresses challenging large vessel cases[3].
- Therapeutic areas
- Cardiovascular
- Modalities
- DeviceEndovenous chemical ablation
- Industry
- Therapeutic Medical Devices
Beyond the preview
Go deeper on VVT Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VVT Medical.